Safety, Pharmacokinetics, and Efficiency of JS005, a Novel Anti-interleukin-17A Monoclonal Antibody, in Healthy Chinese Adults and Patients with Moderate to Severe Psoriasis
DOI:
https://doi.org/10.2340/actadv.v105.41105Keywords:
JS005, anti-IL-17A monoclonal antibody, psoriasisAbstract
JS005 is a novel anti-IL-17A monoclonal antibody. A Phase Ia study (Study 1) in healthy adults, followed by a Phase Ib/II study (Study 2) in patients with moderate to severe plaque psoriasis (PsO), were designed to evaluate the safety, efficacy, and pharmacokinetic characteristics of JS005. Study 1 was a double-blind, randomized, placebo-controlled, single dose-escalation (15, 60, 150, 300, and 600 mg) study. Forty healthy participants were enrolled. Study 2 consisted of a dose-escalation (60, 150, 300, or 600 mg) phase Ib, and a multicentre, double-blind, placebo-controlled phase II administering JS005 150, 300 mg, or placebo once weekly from week 0 to 4 and once every 4 weeks from week 5 to 12. Forty and 143 patients were enrolled in phases Ib and II, respectively. The exposure of JS005 increased linearly with dosage, while the treatment-emergent adverse events did not show this trend. JS005 was well tolerated in both populations. In phase II of Study 2, the proportion of patients with at least a 75% improvement in the Psoriasis Area and Severity Index at week 12 was significantly higher in each JS005 group than in the placebo group (p < 0.001 for all comparisons). JS005 was highly effective in PsO patients.
Downloads
References
Badri T, Kumar P, Oakley AM. Plaque psoriasis. In: StatPearls. Treasure Island, FL: StatPearls Publishing; August 8, 2023.
Kaul M, Jarvis P, Rozenberg I, Kolbinger F, Di Padova F, Calonder C, et al. First-in-human study demonstrating the safety and clinical efficacy of novel anti-IL-17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis. J Eur Acad Dermatol Venereol 2021; 35: 1143–1151.
https://doi.org/10.1111/jdv.17071 DOI: https://doi.org/10.1111/jdv.17071
Campanati A, Marani A, Martina E, Diotallevi F, Radi G, Offidani A. Psoriasis as an immune-mediated and inflammatory systemic disease: from pathophysiology to novel therapeutic approaches. Biomedicines 2021; 9: 1511.
https://doi.org/10.3390/biomedicines9111511 DOI: https://doi.org/10.3390/biomedicines9111511
Griffiths CEM, van der Walt JM, Ashcroft DM, Flohr C, Naldi L, Nijsten T, et al. The global state of psoriasis disease epidemiology: a workshop report. Br J Dermatol 2017; 177: e4–7.
https://doi.org/10.1111/bjd.15610 DOI: https://doi.org/10.1111/bjd.15610
Ogawa E, Sato Y, Minagawa A, Okuyama R. Pathogenesis of psoriasis and development of treatment. J Dermatol 2018; 45: 264–272.
https://doi.org/10.1111/1346-8138.14139 DOI: https://doi.org/10.1111/1346-8138.14139
Malakouti M, Brown G, Wang E, Koo J, Levin E. The role of IL-17 in psoriasis. J Dermatolog Treat 2015; 26: 41–44.
https://doi.org/10.3109/09546634.2013.879093 DOI: https://doi.org/10.3109/09546634.2013.879093
Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis: results of two phase 3 trials. N Engl J Med 2014; 371: 326–338.
https://doi.org/10.1056/NEJMoa1314258 DOI: https://doi.org/10.1056/NEJMoa1314258
Saeki H, Nakagawa H, Ishii T, Morisaki Y, Aoki T, Berclaz PY, et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol 2015; 29: 1148–1155.
https://doi.org/10.1111/jdv.12773 DOI: https://doi.org/10.1111/jdv.12773
Li X, Zheng J, Pan W, Zheng M, Lu Y, Li F, et al. Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 60-week results from a phase 3 study. Int J Dermatol Venerol 2022; 5: 181–190.
https://doi.org/10.1097/JD9.0000000000000244 DOI: https://doi.org/10.1097/JD9.0000000000000244
Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 2016; 375: 345–356.
https://doi.org/10.1056/NEJMoa1512711 DOI: https://doi.org/10.1056/NEJMoa1512711
Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015; 386: 541–551.
https://doi.org/10.1016/S0140-6736(15)60125-8 DOI: https://doi.org/10.1016/S0140-6736(15)60125-8
Ritchlin CT, Kavanaugh A, Merola JF, Schett G, Scher JU, Warren RB, et al. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet 2020; 395: 427–440.
https://doi.org/10.1016/S0140-6736(19)33161-7 DOI: https://doi.org/10.1016/S0140-6736(19)33161-7
Papp KA, Merola JF, Gottlieb AB, Griffiths CEM, Cross N, Peterson L, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2B trial. J Am Acad Dermatol 2018; 79: 277–286.e10.
https://doi.org/10.1016/j.jaad.2018.03.037 DOI: https://doi.org/10.1016/j.jaad.2018.03.037
Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 2015; 373: 1318–1328.
https://doi.org/10.1056/NEJMoa1503824 DOI: https://doi.org/10.1056/NEJMoa1503824
Bausch Health. Highlights of prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761032s014lbl.pdf
Zhang M, Zhu X, Wu J, Huang Z, Zhao Z, Zhang X, et al. Hyperuricemia among Chinese adults: findings from two nationally representative cross-sectional surveys in 2015–16 and 2018–19. Front Immunol 2022; 12: 791983.
https://doi.org/10.3389/fimmu.2021.791983 DOI: https://doi.org/10.3389/fimmu.2021.791983
Cai L, Zhang JZ, Yao X, Gu J, Liu QZ, Zheng M, et al. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis. Chin Med J (Engl) 2020; 133: 2665–2673.
https://doi.org/10.1097/CM9.0000000000001163 DOI: https://doi.org/10.1097/CM9.0000000000001163
Mendes Roncada EV, Brambilla VR, Freitas Filitto B, Genta MP, Morgado de Abreu MAM. Atopic dermatitis as a paradoxical effect of secukinumab for the treatment of psoriasis. Case Rep Dermatol 2021; 13: 336–339.
https://doi.org/10.1159/000513467 DOI: https://doi.org/10.1159/000513467
Al-Janabi A, Foulkes AC, Griffiths CEM, Warren RB. Paradoxical eczema in patients with psoriasis receiving biologics: a case series. Clin Exp Dermatol 2022; 47: 1174–1178.
https://doi.org/10.1111/ced.15130 DOI: https://doi.org/10.1111/ced.15130
Mengesha BG, Conti HR. The role of IL-17 in protection against mucosal candida infections. J Fungi (Basel) 2017; 3: 52.
https://doi.org/10.3390/jof3040052 DOI: https://doi.org/10.3390/jof3040052
Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol 2017; 177: 47–62.
https://doi.org/10.1111/bjd.15015 DOI: https://doi.org/10.1111/bjd.15015
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Lin Cai, Huichen Liu, Zhanglei Mu, Xiaohua Tao, Litao Zhang, Chunlei Zhang, Yumei Li, Guoqiang Zhang, Furen Zhang, Xiuqin Dong, Chengxin Li, Aijun Chen, Zhuning Wu, Yuxian Zhu, Mengqi Zhang, Jiangnian Liu, Aiming Li, Jianzhong Zhang
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
